Pushing the limits of metastasis-directed treatment in metastatic renal cell carcinoma in the era of targeted therapy

Holz, Serge; Tosco, Lorenzo; Akand, Murat; Verbiest, Annelies; Beuselinck, Benoît; Albersen, Maarten; Roussel, Eduard; Poppel, Hein Van; Joniau, Steven

doi:10.1016/j.urolonc.2020.08.017

Cited by 5 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous studies have published data on prognostic factors identified via multivariate analysis in mRCC patients with lung metastases, which include synchronous metastasis, completeness of metastasectomy, and number of metastases (Table 2) (36,46,(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63). In 2021, Meacci et (62).…”

Section: Clinical Outcomes and Complications Of Metastasectomy By Sit...mentioning

confidence: 99%

Role of metastasectomy in the management of renal cell carcinoma

et al. 2022

View full text Add to dashboard Cite

Treatment of metastatic renal cell carcinoma (mRCC) has evolved with the development of a variety of systemic agents; however, these therapies alone rarely lead to a complete response. Complete consolidative surgery with surgical metastasectomy has been associated with improved survival outcomes in well-selected patients in previous reports. No randomized control trial exists to determine the effectiveness of metastasectomy. Therefore, reviewing observational studies is important to best determine which patients are most appropriate for metastasectomy for mRCC and if such treatment continues to be effective with the development of new systemic therapies such as immunotherapy. In this narrative review, we discuss the indications for metastasectomies, outcomes, factors associated with improved survival, and special considerations such as location of metastasis, number of metastases, synchronous metastases, and use of systemic therapy. Additionally, alternative treatment options and trials involving metastasectomy will be reviewed.

show abstract